openPR Logo
Press release

Global anti-obesity drugs market set to grow to $6.3bn by 2023, according to Visiongain report.

04-08-2019 05:50 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: visiongain

Your guide to your industry

Your guide to your industry

Visiongain’ has launched a new pharma report: Global Anti-obesity Drugs Market Forecast 2018-2028: Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs

For free sample pages on this report please click on:
https://www.visiongain.com/report/global-anti-obesity-drugs-market-forecast-2018-2028/#download_sampe_div

The Global Anti-Obesity Drugs Market is segmented into mechanism of action, duration of action, prescription vs. OTC and innovator vs. generic drugs. Mechanism of action (MOA) is further classified as Incretin mimetics/GLP-1 agonists, Lipase inhibitors, Serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI), Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics and others. Most of the anti-obesity drugs have gone off-patent and thus this drug market is also marketed in to two markets as Innovator and Branded drugs. In addition, the market is marketed as prescription and over-the-counter (OTC) based on need for prescription for dispensing the drug.

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 549 9987.

The lead analyst of the report commented “During the forecast period, the global market is driven by the raising prevalence of overweight and obesity population; increasing awareness about the disease; growing diagnosis & treatment rates; obesity being recognized as a disease, adoption of national and international level policies by various countries.

In the global market, challenges continue with huge healthcare budget constraints, weak late-stage promising pipeline, generic competition, unavailability of safer & effective treatments, and availability of alternate therapies.”

Leading companies featured in the report include o Eisai/Arena, GlaxoSmithKline (GSK), Novo Nordisk, Orexigen/Takeda, Roche, Teva, Vivus

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 549 9987.

For more Pharma reports please visit https://www.visiongain.com/industries/pharma/

Related reports:
• Pharma Leader Series: Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market 2018
https://www.visiongain.com/report/pharma-leader-series-top-50-pharmaceutical-contract-manufacturing-organisations-cmos-market-2018/
• Pharma Leader Series: Top Generic Drug Producers Market Forecast 2019-2029
https://www.visiongain.com/report/pharma-leader-series-top-generic-drug-producers-market-forecast-2019-2029/
• Dermatological Drugs Market Forecast 2018-2028
https://www.visiongain.com/report/dermatological-drugs-market-forecast-2018-2028/
• Global Diabetes Drugs Market 2017-2027
https://www.visiongain.com/report/global-diabetes-drugs-market-2017-2027/

Visiongain is one of the fastest-growing and most innovative independent business intelligence providers in Europe.
Based in London, UK, Visiongain publishes independent and insightful market reports across a wide range of industry verticals, including automotive, chemical, cyber, defence, energy, pharmaceutical, materials and many more sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. The company has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original business intelligence to depend upon.
https://www.visiongain.com/

Suite 143, Airport House Purley Way, Croydon CR0 0XZ

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global anti-obesity drugs market set to grow to $6.3bn by 2023, according to Visiongain report. here

News-ID: 1693633 • Views:

More Releases from visiongain

Can Coatings Market Research Report Up to 2031
Can Coatings Market Research Report Up to 2031
Visiongain has published a new report on Can Coatings Market Report to 2031: Segmentation by Type (Epoxy, Oleoresin, Vinyl, Phenolic, Acrylic, Polyester, Polyolefin, Additives, Other Type) Segmentation by Coating Technologies (Conventional solvent borne coatings, High-solids coatings, Waterborne coatings, Ultraviolet radiation-cured (UV-cured) coatings, Powder coatings, Other Technologies) Segmentation by Application (Food Can, Beverage Can, General Line Can, Aerosol Can, Others, Other Application) PLUS COVID-19 Impact Analysis and Recovery Pattern Analysis (V-shaped,
Automatic Number Plate Recognition (ANPR) System Market Report Up to 2031
Automatic Number Plate Recognition (ANPR) System Market Report Up to 2031
Visiongain has published a new report on Automatic Number Plate Recognition (ANPR) System Market Report to 2031: Forecasts by component (Hardware, Software, Services), by type (Fixed ANPR Systems, Portable ANPR Systems), by application (Traffic Management, Law Enforcement, Electronic Toll Collection, Others). PLUS Profiles of Leading Automatic Number Plate Recognition System Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios. Download Exclusive Sample of Report @ https://www.visiongain.com/report/anpr-system-market/#download_sampe_div Automatic number plate
Automatic Labelling Machine Market Report Up to 2031
Automatic Labelling Machine Market Report Up to 2031
Visiongain has published a new report on Automatic Labelling Machine Market Report to 2031: Forecasts by type (Stretch Sleeve Labelers, Shrink-Sleeve Labelers, Glue-based Labelers, Others), by industry vertical (Consumer Goods, Food & Beverages, Automotive, Pharmaceuticals, Others). PLUS Profiles of Leading Automatic Labelling Machine Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios. Download Exclusive Sample of Report @ https://www.visiongain.com/report/automatic-labelling-machine-market/#download_sampe_div An automatic labeling machine is designed to print-and-apply labels to
Atomic Absorption Spectrometer Market Report Up to 2031
Visiongain has published a new report on Atomic Absorption Spectrometer Market Report to 2031: Forecasts by type (Х-rау Dіffrасtіоn Ѕресtrоmеtrу, Х-rау Fluоrеѕсеnсе Ѕресtrоmеtrу, Others), by application (Рhаrmасеutісаl, Mining Industry, Petrochemical Industry, Fооd & Веvеrаgе, Others). PLUS Profiles of Leading Atomic Absorption Spectrometer Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios. Download Exclusive Sample of Report @ https://www.visiongain.com/report/atomic-absorption-spectrometer-market/#download_sampe_div Atomic absorption spectrometer is the determination of elemental composition and is

All 5 Releases


More Releases for Drug

Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June. The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug